Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Mouse Models as a Tool for Understanding Progression in BrafV600E-Driven Thyroid Cancers.

Landa I, Knauf JA.

Endocrinol Metab (Seoul). 2019 Mar;34(1):11-22. doi: 10.3803/EnM.2019.34.1.11. Epub 2019 Feb 15. Review.

2.

Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies.

Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE.

Clin Cancer Res. 2019 May 15;25(10):3141-3151. doi: 10.1158/1078-0432.CCR-18-2953. Epub 2019 Feb 8.

PMID:
30737244
3.

Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR.

Mol Cancer Res. 2019 May;17(5):1036-1048. doi: 10.1158/1541-7786.MCR-18-1026. Epub 2019 Feb 7.

PMID:
30733375
4.

EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC.

Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, Wendel HG, Dogan S, Tamarapu PP, Blenis J, Ghossein RA, Knauf JA, Rätsch G, Fagin JA.

Cancer Discov. 2019 Feb;9(2):264-281. doi: 10.1158/2159-8290.CD-18-0606. Epub 2018 Oct 10.

PMID:
30305285
5.

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.

Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Ni A, Li D, Knauf JA, Pfister DG, Fagin JA, Ho AL.

J Clin Endocrinol Metab. 2019 May 1;104(5):1417-1428. doi: 10.1210/jc.2018-01478.

PMID:
30256977
6.

Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.

Knauf JA, Luckett KA, Chen KY, Voza F, Socci ND, Ghossein R, Fagin JA.

J Clin Invest. 2018 Aug 31;128(9):4086-4097. doi: 10.1172/JCI120966. Epub 2018 Aug 20.

7.

Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.

Marlow LA, Rohl SD, Miller JL, Knauf JA, Fagin JA, Ryder M, Milosevic D, Netzel BC, Grebe SK, Reddi HV, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3169-3182. doi: 10.1210/jc.2017-01845.

PMID:
29846633
8.

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.

Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamoorthy GP, Saqcena M, Bhanot UK, Socci ND, Ho AL, Ghossein R, Fagin JA.

Cancer Res. 2018 Aug 15;78(16):4642-4657. doi: 10.1158/0008-5472.CAN-17-1925. Epub 2018 May 14.

PMID:
29760048
9.

Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia.

Bellelli R, Vitagliano D, Federico G, Marotta P, Tamburrino A, Salerno P, Paciello O, Papparella S, Knauf JA, Fagin JA, Refetoff S, Troncone G, Santoro M.

Mol Cell Endocrinol. 2018 Jan 15;460:24-35. doi: 10.1016/j.mce.2017.06.023. Epub 2017 Jun 23.

10.

Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence.

Ibrahimpasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, Deraje S, Carlson DL, Migliacci J, Knauf JA, Untch B, Berger MF, Morris L, Tuttle RM, Chan T, Fagin JA, Ghossein R, Ganly I.

Clin Cancer Res. 2017 Oct 1;23(19):5970-5980. doi: 10.1158/1078-0432.CCR-17-1183. Epub 2017 Jun 20.

11.

Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene.

Montero-Conde C, Leandro-Garcia LJ, Chen X, Oler G, Ruiz-Llorente S, Ryder M, Landa I, Sanchez-Vega F, La K, Ghossein RA, Bajorin DF, Knauf JA, Riordan JD, Dupuy AJ, Fagin JA.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):E4951-E4960. doi: 10.1073/pnas.1702723114. Epub 2017 Jun 5.

12.

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M, Larson SM, Ho AL, Seshan V, Ishii N, Carrasco N, Rosen N, Weber WA, Fagin JA.

J Clin Invest. 2016 Nov 1;126(11):4119-4124. doi: 10.1172/JCI89067. Epub 2016 Sep 26.

13.

NADPH Oxidase NOX4 Is a Critical Mediator of BRAFV600E-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas.

Azouzi N, Cailloux J, Cazarin JM, Knauf JA, Cracchiolo J, Al Ghuzlan A, Hartl D, Polak M, Carré A, El Mzibri M, Filali-Maltouf A, Al Bouzidi A, Schlumberger M, Fagin JA, Ameziane-El-Hassani R, Dupuy C.

Antioxid Redox Signal. 2017 May 20;26(15):864-877. doi: 10.1089/ars.2015.6616. Epub 2016 Aug 22.

14.

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA.

J Clin Invest. 2016 Mar 1;126(3):1052-66. doi: 10.1172/JCI85271. Epub 2016 Feb 15.

15.

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

Garcia-Rendueles ME, Ricarte-Filho JC, Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giancotti F, Ghossein R, Fagin JA.

Cancer Discov. 2015 Nov;5(11):1178-93. doi: 10.1158/2159-8290.CD-15-0330. Epub 2015 Sep 10.

16.

Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Malaguarnera R, Chen KY, Kim TY, Dominguez JM, Voza F, Ouyang B, Vundavalli SK, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2014 Oct;99(10):E1976-87. doi: 10.1210/jc.2013-3976. Epub 2014 Jul 16.

17.

Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.

Chen X, Makarewicz JM, Knauf JA, Johnson LK, Fagin JA.

Oncogene. 2014 Nov 20;33(47):5442-9. doi: 10.1038/onc.2013.489. Epub 2013 Nov 18.

18.

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.

Ricarte-Filho JC, Li S, Garcia-Rendueles ME, Montero-Conde C, Voza F, Knauf JA, Heguy A, Viale A, Bogdanova T, Thomas GA, Mason CE, Fagin JA.

J Clin Invest. 2013 Nov;123(11):4935-44. doi: 10.1172/JCI69766. Epub 2013 Oct 25.

19.

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.

Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA, Fagin JA.

Endocr Relat Cancer. 2013 Aug 21;20(5):659-67. doi: 10.1530/ERC-13-0085. Print 2013 Oct.

20.

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA.

Cancer Discov. 2013 May;3(5):520-33. doi: 10.1158/2159-8290.CD-12-0531. Epub 2013 Jan 29.

21.

STAT3 negatively regulates thyroid tumorigenesis.

Couto JP, Daly L, Almeida A, Knauf JA, Fagin JA, Sobrinho-Simões M, Lima J, Máximo V, Soares P, Lyden D, Bromberg JF.

Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):E2361-70. doi: 10.1073/pnas.1201232109. Epub 2012 Aug 13.

22.

GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sjögren I, Andersen S, Andersen L, de Boer AS, Manova K, Barlas A, Vundavalli S, Nyborg NC, Knudsen LB, Moelck AM, Fagin JA.

Endocrinology. 2012 Mar;153(3):1538-47. doi: 10.1210/en.2011-1864. Epub 2012 Jan 10.

23.

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA.

J Clin Invest. 2011 Dec;121(12):4700-11. doi: 10.1172/JCI46382. Epub 2011 Nov 21.

24.

Does the epidermal growth factor receptor play a role in the progression of thyroid cancer?

Knauf JA.

Thyroid. 2011 Nov;21(11):1171-4. doi: 10.1089/thy.2011.2111.ed. No abstract available.

PMID:
22050034
25.

Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment.

Read ML, Lewy GD, Fong JC, Sharma N, Seed RI, Smith VE, Gentilin E, Warfield A, Eggo MC, Knauf JA, Leadbeater WE, Watkinson JC, Franklyn JA, Boelaert K, McCabe CJ.

Cancer Res. 2011 Oct 1;71(19):6153-64. doi: 10.1158/0008-5472.CAN-11-0720. Epub 2011 Aug 15.

26.

Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.

Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA.

Oncogene. 2011 Jul 14;30(28):3153-62. doi: 10.1038/onc.2011.44. Epub 2011 Mar 7.

27.

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1615-20. doi: 10.1073/pnas.1015557108. Epub 2011 Jan 10.

28.

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA.

Cancer Res. 2009 Jun 1;69(11):4885-93. doi: 10.1158/0008-5472.CAN-09-0727.

29.

Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene.

Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo VA, Mitsutake S, Kimura ET, Geiger H, Santos E, Wendel HG, Franco A, Knauf JA, Fagin JA.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7979-84. doi: 10.1073/pnas.0900343106. Epub 2009 Apr 29.

30.

Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets.

Knauf JA, Fagin JA.

Curr Opin Cell Biol. 2009 Apr;21(2):296-303. doi: 10.1016/j.ceb.2009.01.013. Epub 2009 Feb 21. Review.

PMID:
19231149
31.

Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer.

Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA.

Endocr Relat Cancer. 2008 Dec;15(4):1069-74. doi: 10.1677/ERC-08-0036. Epub 2008 Aug 21.

32.

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR.

J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41. doi: 10.1210/jc.2008-1102. Epub 2008 Aug 19.

33.

RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA.

Cancer Res. 2008 Jun 1;68(11):4183-91. doi: 10.1158/0008-5472.CAN-08-0413.

34.

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201. doi: 10.1210/jc.2007-2825. Epub 2008 Apr 1.

35.

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA.

Cancer Res. 2007 Jul 15;67(14):6956-64.

36.

Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.

Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA.

Cancer Res. 2006 Jul 1;66(13):6521-9.

37.

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.

Clin Cancer Res. 2006 Mar 15;12(6):1785-93.

38.

Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints.

Knauf JA, Ouyang B, Knudsen ES, Fukasawa K, Babcock G, Fagin JA.

J Biol Chem. 2006 Feb 17;281(7):3800-9. Epub 2005 Nov 29.

39.

BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.

Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C Jr, Knauf JA, Zhang L, Taira K, Fagin JA.

Endocrinology. 2006 Feb;147(2):1014-9. Epub 2005 Oct 27.

PMID:
16254036
40.

RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response.

Puxeddu E, Knauf JA, Sartor MA, Mitsutake N, Smith EP, Medvedovic M, Tomlinson CR, Moretti S, Fagin JA.

Endocr Relat Cancer. 2005 Jun;12(2):319-34.

PMID:
15947106
41.

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.

Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA.

Cancer Res. 2005 May 15;65(10):4238-45.

42.

Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.

Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA.

Cancer Res. 2005 Mar 15;65(6):2465-73.

43.

BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer.

Ciampi R, Knauf JA, Rabes HM, Fagin JA, Nikiforov YE.

Cell Cycle. 2005 Apr;4(4):547-8. Epub 2005 Apr 24. Review.

PMID:
15753649
44.

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE.

J Clin Invest. 2005 Jan;115(1):94-101.

45.

Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.

Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov YE.

Cancer Lett. 2004 Jun 8;209(1):1-6.

PMID:
15145515
46.

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE.

J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404.

PMID:
14602780
47.

Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.

Puxeddu E, Mitsutake N, Knauf JA, Moretti S, Kim HW, Seta KA, Brockman D, Myatt L, Millhorn DE, Fagin JA.

J Biol Chem. 2003 Dec 26;278(52):52131-8. Epub 2003 Oct 10.

48.

Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells.

Knauf JA, Ouyang B, Croyle M, Kimura E, Fagin JA.

Oncogene. 2003 Oct 9;22(44):6830-8.

PMID:
14534528
49.

RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.

Knauf JA, Kuroda H, Basu S, Fagin JA.

Oncogene. 2003 Jul 10;22(28):4406-12.

PMID:
12853977
50.

Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.

Wang J, Knauf JA, Basu S, Puxeddu E, Kuroda H, Santoro M, Fusco A, Fagin JA.

Mol Endocrinol. 2003 Jul;17(7):1425-36. Epub 2003 Apr 10.

PMID:
12690093

Supplemental Content

Loading ...
Support Center